Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis C virus NS3/4A protease

A D Kwong1, J L Kim, G Rao

  • 1Vertex Pharmaceuticals, Inc., Cambridge, MA 02139, USA. kwong@vpharm.com

Antiviral Research
|December 24, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing adaptation and learning in educational environments (SENSE project): a case series study.

Frontiers in psychiatry·2026
Same author

Anomalous vertebral artery course causing radiculopathy: A case report and review of relevant literature.

Brain & spine·2026
Same author

Effectiveness and feasibility of a theory-informed intervention to improve Mediterranean diet adherence, physical activity and cognition in older adults at risk of dementia: the MedEx-UK randomised controlled trial.

BMC medicine·2024
Same author

The impact of transplant location on the gut microbiome and resistome in patients undergoing hematopoietic stem cell transplantation at home versus in the hospital.

bioRxiv : the preprint server for biology·2024
Same author

Long-term follow-up of bulky classic Hodgkin lymphoma managed with ABVD and PET-guided RT demonstrates excellent outcomes in PET-negative cases.

British journal of haematology·2024
Same author

Value of long non-coding RNA HAS2-AS1 as a diagnostic and prognostic marker of glioma.

Neurologia·2024
Same journal

Nanoparticles in viral pneumonia: diagnosis, therapy, and prevention.

Antiviral research·2026
Same journal

The anti-respiratory syncytial virus activity of biochemicals from Pyrola incarnata.

Antiviral research·2026
Same journal

Ginsenoside Rb2-based inactivation enables a Zika vaccine that maintains pregnancy and protects offspring against virus.

Antiviral research·2026
Same journal

ITGA4 drives pathogenesis of flavivirus and inhibition of it protects mice against Japanese encephalitis virus infection.

Antiviral research·2026
Same journal

Corrigendum to "A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2" [Antivir. Res. 225 (2024) 105854].

Antiviral research·2026
Same journal

Effects of RNA polymerase inhibitors on nucleotidylylation of human norovirus VPg.

Antiviral research·2026
See all related articles

Developing effective antiviral therapies for hepatitis C virus (HCV) remains critical. This review explores inhibitors targeting the HCV NS3/4A serine protease, crucial for viral replication.

Area of Science:

  • Virology
  • Drug Discovery
  • Biochemistry

Background:

  • Hepatitis C virus (HCV) infections lack broad antiviral therapies.
  • HCV polyprotein processing by NS3/4A protease is essential for viral replication.
  • NS3/4A protease activity is a key target for antiviral drug development.

Purpose of the Study:

  • To review the structure and function of the NS3/4A serine protease.
  • To discuss the development of small molecule inhibitors targeting NS3/4A protease activity.

Main Methods:

  • Focuses on structural and functional analysis of the NS3/4A protease complex.
  • Reviews existing literature on NS3/4A protease inhibitor development.

Main Results:

Related Experiment Videos

  • The NS3/4A complex is a validated target for HCV antiviral therapy.
  • Small molecule inhibitors targeting NS3/4A protease show promise.

    • Conclusions:

    • Inhibiting the NS3/4A serine protease is a viable strategy for developing novel HCV antivirals.
    • Further research into NS3/4A protease inhibitors is warranted to address the urgent medical need for effective HCV treatments.